Asta Medica, Aktiengesellschaft

Zentaris Ag

Other

Zentaris Gmbh

Baxter Healthcare Sa

Asta Pharma Aktiengesellschaft

Viatris Gmbh & Co Kg

J&uuml;rgen Engel

Bernd Nickel

Peter Hilgard

Thomas Reissmann

Thomas Klenner

Helmut Hettche

Burkhard Wichert

Michael Lobisch

Hansj&ouml;rg Eibl

Clemens Unger

Hilde Riethm&uuml;ller-Winzen

Bernhard Kutscher

Thomas Beckers

Peter Emig

Dieter Sauerbier

Joachim Goede

Hildegard Poppe

Heinz Ulrich

Michael Damm

Wolfgang Schumacher

Klaus Wessel

Gerald Bacher

Jurij Stekar

Harald Borbe

Carl-Heinrich Weischer

Horst Bauer

Helmut Momberger

Erik Bruyneel

Kirsten Peters

Gerhard N&ouml;ssner

Istv&aacute;n Szel&eacute;nyi

J&uuml;rgen Rawert

Waldemar Salonek

Jean Schoenen

Gabriele Stach

Manfred Peukert

Thomas Reissman

Dieter Eauerbiar

G&uuml;nter Kamp

A novel lyophilizate and method of preparation as well as the use of the lyophilizate to treat female infertility and for gonad protection. Cetrorelix is dissolved in acetic acid 30% v/v, the solution is transferred to water and freeze dried.

Oligopeptide lyophilisate, their preparation and use

A method for producing peptide salts, including reacting an acid addition salt of a basic starting peptide in the presence of a diluent in a mixed bed ion exchanger, with a mixture of an acid and a basic ion exchanger during the formation of a free basic peptide, and then separating the ion exchanger and then the free basic peptide, with an inorganic or organic acid, and then forming the desired acid addition salt of the peptide, and removing the diluent.

Method for the synthesis of peptide salts, their use and the pharmaceutical preparations, containing peptide salts

A method of treating female infertility using a novel cetrorelix acetate lyophilizate is disclosed.

Method of treatment of female infertility

The side effect of decrease in body weight caused by the alkylphosphocholines such as miltefosine can be antagonized by certain acetylcholine receptor antagonists such as domperidone and pimozide. The combination of alkylphosphocholine plus the antagonist does not have any effect on the anti-tumor action of the alkylphosphocholine. The combination also caused no new side effects in the animals.

Use of dopamine receptor antagonists in palliative tumor therapy

Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties

Pharmaceutical dosage units containing flupirtine or a pharmaceutically acceptable salt of flupirtine with controlled release of active substance using a delayed-action or controlled-release component. There are 0.001 to 20 parts delayed-action component for each part by weight flupirtine (calculated as the base) and the release rate of flupirtine is between 5 and 300 mg per hour. In some cases, the dosage units may also contain a rapidly releasing component of flupirtine or of one of its salts. The dosage units reduce the sedative effect of flupirtine.

Oral forms of administration containing solid flupirtine with controlled release of active substance

Methods of treating protozoal diseases

A method of treating protozoal and fungal diseases is described, in which an effective amount of a compound of formula I is administered to a host having a protozoal or fungal disease. Also described are methods of treating bone marrow damage composed of administering, to a host having bone marrow damage due to treatment with cytostatic agents or other myelotoxic active ingredients, an effective amount of a compound of formula I

Methods of using therapeutic phospholipid derivatives

The invention relates to a pharmaceutical composition for the treatment of allergic rhinitis, vasomotor rhinitis, and allergic conjunctivitis, which comprises (a) a nonsedating antihistamine or a pharmaceutically acceptable salt thereof, (b) a leukotriene D antagonist, or a 5-lipoxygenase inhibitor, or a FLAP antagonist, or a pharmaceutically acceptable salt thereof, and (c) one or more of a conventional pharmaceutical vehicle, extender, and excipient, and to its use for manufacturing a composition for the treatment of allergic rhinitis, vasomotor rhinitis, and allergic conjunctivitis.

Antihistamine leukotriene combinations

An improvement to the method of intrauterine insemination by the administration of luteinizing hormone-releasing hormone antagonists (LHRH antagonists).

Method for the treatment of fertility disorders

A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs Cetrorelix alone or in combination with &agr;-reductase inhibitors or &agr;-receptor blocking agents. The regiment reduces the volume of the prostate and avoids the side effects associated with testosterone levels being in a castration range. Cetrorelix is administered at dosages between 0.5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per day to 0.30 mg/kg body weight per week or at levels of about 25 to 120 mg of Cetrorelix per month or 0.376 mg/kg to 1.71 mg/kg per month. Cetrorelix can be administered with &agr;-reductase inhibitors or a &agr;-receptor blocking agents.

Means for treating prostate hypertrophy and prostate cancer

Pharmaceutical compositions and processes for their preparation containing R-&agr;-lipoic acid or S-&agr;-lipoic acid or pharmaceutically acceptable salts thereof. The pharmaceutical compositions have a cytoprotective activity and are suitable for combatting pain and inflammation.

Pharmaceutical compositions containing R-&agr;-lipoic acid or S-&agr;-lipoic acid as active ingredient

The invention concerns a new pharmaceutical agent for oral or topical administration in the treatment of protozoal diseases, in particular of leishmaniasis, which contains as the active substance one or several compounds having the general formula I

The invention relates to the use of racemic &agr;-lipoic acid or its enantiomers or pharmaceutically acceptable salts, amides, esters or thioesters thereof, in reduced or oxidized form, as active ingredient in the prevention or the acute or chronic treatment of migraine.

Treatment of migraine by administration of &agr;-lipoic acid or derivatives thereof

Growing community of inventors

Alzenau, Germany

Jürgen Engel

Growing community of inventors

Alzenau, Germany

J&uuml;rgen Engel

Jürgen Engel